Skip to main content
Cartesian Therapeutics, Inc. logo

Cartesian Therapeutics, Inc. — Investor Relations & Filings

Ticker · RNAC ISIN · US8162121045 US Manufacturing
Open in API
Filings indexed 853 across all filing types
Latest filing 2015-12-29 Capital/Financing Update
Country US United States of America
Listing US RNAC

About Cartesian Therapeutics, Inc.

https://www.cartesiantherapeutics.com/

Cartesian Therapeutics, Inc. is a clinical-stage company that pioneers the development of mRNA-engineered cell therapies. The company's primary focus is on creating treatments for autoimmune diseases. Leveraging its novel mRNA technology platform, Cartesian develops therapeutic cells designed to target the drivers of these conditions. This approach aims to expand the reach and potential of cell therapy for patients with various autoimmune disorders. The company's lead asset, Descartes-08, is a central component of its clinical pipeline.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2015
Capital/Financing Update Classification · 95% confidence The document is a detailed response letter from a company to the SEC staff regarding comments on a Confidential Draft Registration Statement on Form S-1. It discusses revisions to the Registration Statement, including prospectus summary, risk factors, use of proceeds, management's discussion and analysis, business overview, clinical trials, licenses, and intellectual property disclosures. The presence of the Form S-1 draft registration statement and the nature of the content indicate this is related to a company's IPO registration process, which is a capital raising activity. The document is not the registration statement itself but a comment letter and response to SEC staff comments on the draft registration statement. Therefore, it is an update related to capital raising and financing activities, not a financial report or earnings release. The best fitting category is Capital/Financing Update (CAP).
2015-12-29 English
Capital/Financing Update 2015
Capital/Financing Update Classification · 100% confidence The document is a confidential submission to the SEC on Form S-1, which is a registration statement under the Securities Act of 1933. It includes a preliminary prospectus for an initial public offering (IPO) of common stock. The text references the registration process, underwriting, offering price, and other IPO-related details. This type of filing is related to capital raising and financing activities. Therefore, it fits the category of Capital/Financing Update (CAP). The document is not an annual report, earnings release, or any other report type but a registration statement for securities offering.
2015-12-29 English
Regulatory Filings 2015
Regulatory Filings
2015-12-18 English
Capital/Financing Update 2015
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed confidentially with the SEC, dated November 24, 2015, for Selecta Biosciences, Inc. It is a preliminary prospectus for an initial public offering (IPO) of common stock. The text includes details about the offering, underwriting, risk factors, management discussion, financial data, and other disclosures typical of an IPO registration statement. This type of filing is related to capital raising and securities registration, which aligns with Capital/Financing Update filings. It is not an annual report, earnings release, or any other report type. Therefore, the correct classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains substantive content, not just an announcement or certification, supporting a high confidence score.
2015-11-24 English
Regulatory Filings 2015
Regulatory Filings
2015-09-10 English
Regulatory Filings 2015
Regulatory Filings
2015-04-22 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.